Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial by Mateo, J et al.
162 www.thelancet.com/oncology   Vol 21   January 2020
Articles
Lancet Oncol 2020; 21: 162–74
Published Online 
December 2, 2019 
https://doi.org/10.1016/ 
S1470-2045(19)30684-9
See Comment page 17
*Contributed equally
†Co-senior authors
The Institute of Cancer 
Research and The Royal 
Marsden NHS Foundation 
Trust, London, UK (J Mateo MD, 
D Bianchini MD, P Rescigno MD, 
A Curcean MD, R Chandler MD, 
N Tunariu MD, 
Prof J S de Bono MD); 
The Institute of Cancer 
Research, London, UK 
(N Porta PhD, S Miranda BSc, 
I Figueiredo BSc, G Seed MSc, 
C Bertan MSc, P Flohr BSc, 
B Ebbs BSc, G Fowler BSc, 
A Ferreira MSc, R Riisnaes FIBMS, 
R Pereira BSc, M Clarke BSc, 
B Gurel MD, M Crespo MSc, 
D Nava Rodrigues MD, 
A Espinasse MSc, P Chatfield BSc, 
W Yuan PhD, Prof E Hall PhD, 
S Carreira PhD); University 
College Hospital, University 
College London Hospitals NHS 
Foundation Trust, London, UK 
(U McGovern MD); The Christie 
NHS Foundation Trust, 
Manchester, UK (T Elliott MD); 
University of Glasgow and 
Beatson West of Scotland 
Cancer Centre, Glasgow, UK 
(Prof R Jones MD); 
The Clatterbridge Cancer 
Centre, Wirral, UK 
(I Syndikus MD); St James’s 
Institute of Oncology, 
University of Leeds, Leeds, UK 
(C Ralph MD); Queen’s 
University, Belfast, UK 
(S Jain MD); Musgrove Park 
Hospital, Taunton, UK 
(M Varughese FRCR); Royal 
Blackburn Hospital, Blackburn, 
UK (O Parikh FRCR); University 
of Southampton, 
Olaparib in patients with metastatic castration-resistant 
prostate cancer with DNA repair gene aberrations (TOPARP-B): 
a multicentre, open-label, randomised, phase 2 trial
Joaquin Mateo*, Nuria Porta*, Diletta Bianchini, Ursula McGovern, Tony Elliott, Robert Jones, Isabel Syndikus, Christy Ralph, Suneil Jain, 
Mohini Varughese, Omi Parikh, Simon Crabb, Angus Robinson, Duncan McLaren, Alison Birtle, Jacob Tanguay, Susana Miranda, Ines Figueiredo, 
George Seed, Claudia Bertan, Penny Flohr, Berni Ebbs, Pasquale Rescigno, Gemma Fowler, Ana Ferreira, Ruth Riisnaes, Rita Pereira, Andra Curcean, 
Robert Chandler, Matthew Clarke, Bora Gurel, Mateus Crespo, Daniel Nava Rodrigues, Shahneen Sandhu, Aude Espinasse, Peter Chatfield, 
Nina Tunariu, Wei Yuan, Emma Hall†, Suzanne Carreira†, Johann S de Bono†
Summary
Background Metastatic castration-resistant prostate cancer is enriched in DNA damage response (DDR) gene 
aberrations. The TOPARP-B trial aims to prospectively validate the association between DDR gene aberrations and 
response to olaparib in metastatic castration-resistant prostate cancer.
Methods In this open-label, investigator-initiated, randomised phase 2 trial following a selection (or pick-the-
winner) design, we recruited participants from 17 UK hospitals. Men aged 18 years or older with progressing 
metastatic castration-resistant prostate cancer previously treated with one or two taxane chemotherapy regimens 
and with an Eastern Cooperative Oncology Group performance status of 2 or less had tumour biopsies tested with 
targeted sequencing. Patients with DDR gene aberrations were randomly assigned (1:1) by a computer-generated 
minimisation method, with balancing for circulating tumour cell count at screening, to receive 400 mg or 300 mg 
olaparib twice daily, given continuously in 4-week cycles until disease progression or unacceptable toxicity. Neither 
participants nor investigators were masked to dose allocation. The primary endpoint of confirmed response was 
defined as a composite of all patients presenting with any of the following outcomes: radiological objective 
response (as assessed by Response Evaluation Criteria in Solid Tumors 1.1), a decrease in prostate-specific antigen 
(PSA) of 50% or more (PSA50) from baseline, or conversion of circulating tumour cell count (from ≥5 cells per 
7·5 mL blood at baseline to <5 cells per 7·5 mL blood). A confirmed response in a consecutive assessment after at 
least 4 weeks was required for each component. The primary analysis was done in the evaluable population. If at 
least 19 (43%) of 44 evaluable patients in a dose cohort responded, then the dose cohort would be considered 
successful. Safety was assessed in all patients who received at least one dose of olaparib. This trial is registered at 
ClinicalTrials.gov, NCT01682772. Recruitment for the trial has completed and follow-up is ongoing.
Findings 711 patients consented for targeted screening between April 1, 2015, and Aug 30, 2018. 161 patients had 
DDR gene aberrations, 98 of whom were randomly assigned and treated (49 patients for each olaparib dose), 
with 92 evaluable for the primary endpoint (46 patients for each olaparib dose). Median follow-up was 24·8 months 
(IQR 16·7–35·9). Confirmed composite response was achieved in 25 (54·3%; 95% CI 39·0–69·1) of 
46 evaluable patients in the 400 mg cohort, and 18 (39·1%; 25·1–54·6) of 46 evaluable patients in the 300 mg 
cohort. Radiological response was achieved in eight (24·2%; 11·1–42·3) of 33 evaluable patients in the 400 mg 
cohort and six (16·2%; 6·2–32·0) of 37 in the 300 mg cohort; PSA50 response was achieved in 17 (37·0%; 
23·2–52·5) of 46 and 13 (30·2%; 17·2–46·1) of 43; and circulating tumour cell count conversion was achieved in 
15 (53·6%; 33·9–72·5) of 28 and 13 (48·1%; 28·7–68·1) of 27. The most common grade 3–4 adverse event in both 
cohorts was anaemia (15 [31%] of 49 patients in the 300 mg cohort and 18 [37%] of 49 in the 400 mg cohort). 
19 serious adverse reactions were reported in 13 patients. One death possibly related to treatment (myocardial 
infarction) occurred after 11 days of treatment in the 300 mg cohort.
Interpretation Olaparib has antitumour activity against metastatic castration-resistant prostate cancer with DDR gene 
aberrations, supporting the implementation of genomic stratification of metastatic castration-resistant prostate 
cancer in clinical practice.
Funding Cancer Research UK, AstraZeneca, Prostate Cancer UK, the Prostate Cancer Foundation, the Experimental 
Cancer Medicine Centres Network, and the National Institute for Health Research Biomedical Research Centres.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 
4.0 license
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Introduction
Molecular stratification for treatment is not currently the 
standard of care for metastatic prostate cancers despite 
evidence of substantial interpatient genomic hetero­
geneity. Most therapeutic strategies for advanced prostate 
cancers target androgen receptor signalling; taxane­
based chemotherapies and radiopharmaceuticals are also 
approved.1 Although these drugs have improved 
outcomes in the past decade, metastatic prostate cancer 
remains invariably fatal and new therapeutic strategies 
involving molecular stratification are urgently needed. 
Genomic studies of metastatic prostate cancer have 
identified a number of potentially actionable recurrent 
genomic aberrations,2–4 including loss­of­function 
alterations in DNA repair genes in 20–25% of cases, such 
as defects in homologous recombination­mediated 
repair genes.3 Among these, germline or somatic 
alterations in BRCA2 are the most common, accounting 
for 6–12% of cases across studies.2–4 These data underpin 
the evaluation of poly(ADP­ribose) polymerase (PARP) 
inhibitors in metastatic prostate cancer.5,6
Olaparib is an orally bioavailable inhibitor of the 
catalytic activity of PARP1 and PARP2, which have key 
roles in DNA damage response (DDR). Olaparib is 
approved for the treatment of advanced ovarian and 
breast cancers associated with germline BRCA1 or 
BRCA2 mutations.7 It is also approved as a maintenance 
therapy after response to platinum­based chemotherapy 
for ovarian cancer, indicating benefit from PARP 
inhibition beyond tumours with BRCA1/2 mutations.8,9 
Furthermore, olaparib has antitumour activity in vitro 
and in vivo in models that are defective in other DDR 
proteins, including PALB2, ATM, FANCD2, RAD51, and 
RAD54, among others, although the magnitude of 
preclinical sensitisation varies between proteins, with 
BRCA2 loss being arguably the most potent sensitising 
event.10,11
To evaluate the antitumour activity of olaparib against 
metastatic castration­resistant prostate cancer, we 
designed TOPARP, an adaptive programme of serial 
phase 2 clinical trials aimed at identifying predictive 
biomarkers for response to PARP inhibition in metastatic 
castration­resistant prostate cancer. In the first trial, 
TOPARP­A, we identified an association between 
putatively deleterious DDR gene aberrations and res­
ponse to olaparib in 49 molecularly unselected patients.12 
In this Article, we present the results of TOPARP­B, 
which was designed to validate the observed antitumour 
activity of olaparib in patients with metastatic castration­
resistant prostate cancer presenting with DDR gene 
aberrations.
Methods
Study design and participants
TOPARP­B is a multicentre, open­label, investigator­
initiated, randomised phase 2 trial. Patients were 
recruited from 17 UK hospitals (appendix p 2).
Patients with prostate cancer that had developed 
metastasis and castration resistance were first registered 
on the trial for molecular preselection by targeted next­
generation sequencing (NGS) of primary or metastatic 
prostate cancer biopsies. Eligible patients were men aged 
18 years or older, with histologically confirmed prostate 
adeno carcinoma (metastatic and castration­resistant), 
and whose tumours had a putatively pathogenic mutation 
or homozygous deletion in a DDR gene that could be 
Research in context
Evidence before this study
Trials for advanced prostate cancer have rarely pursued 
molecular stratification, and none of the drugs approved to date 
for metastatic prostate cancer care have a validated companion 
biomarker. Before starting this study, several genomic landscape 
studies were published describing an enrichment for aberrations 
in DNA repair genes in metastatic prostate cancers (studies 
identified in PubMed, searching for “prostate cancer”, 
“genomics”, and “biopsy”, between Jan 1, 2010 and Nov 1, 2015, 
with no language restrictions). Preclinical and clinical studies 
identified in PubMed (searching for “cancer”, “PARP”, and 
“BRCA” or “DNA repair” between Jan 1, 2005 and July 1, 2019, 
with no language restrictions) have established a correlation 
between different DNA repair defects and sensitivity to PARP 
inhibition in different tumour types, leading to drug approvals 
in ovarian and breast cancer. In the TOPARP-A trial, we identified 
an association between somatic alterations in DNA repair 
genes and antitumour activity of olaparib in 49 patients with 
metastatic prostate cancer. Other clinical trials of PARP 
inhibitors in prostate cancer were identified on the 
ClinicalTrials.gov website, searching for “prostate cancer” and 
“PARP” for studies published from database inception to 
July 1, 2019, without language restriction.
Added value of this study
To our knowledge, TOPARP-B is the first prospective clinical trial 
in a genomically defined population of patients with metastatic 
prostate cancer. TOPARP-B aimed to clinically qualify a predictive 
biomarker for treating metastatic prostate cancer. TOPARP-B 
also assessed different doses of olaparib, and correlated different 
genomic aberrations and antitumour activity. This study has 
confirmed the antitumour activity of olaparib against metastatic 
prostate cancer with defective DNA repair secondary to either 
germline or somatic gene inactivation.
Implications of all the available evidence
Randomised phase 3 trials for DNA repair-defective prostate 
cancers are now ongoing based on the TOPARP data. Our 
results, if confirmed in registration studies, would support the 
implementation of tumour genomic testing in clinical practice 
for treatment stratification in advanced prostate cancer.
See Online for appendix
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associated with sensitivity to PARP inhibition as 
identified by NGS. Patients were required to have 
previously received at least one but no more than two 
taxane­based chemotherapy regimens, regardless of 
prior exposure to novel hormonal drugs. Other inclusion 
criteria included: documented prostate cancer progres­
sion at trial entry, defined by either rising prostate­
specific antigen (PSA) serum concentration (according to 
the Prostate Cancer Working Group 2 [PCWG2] criteria13) 
or radiologically (according to modified Response 
Evaluation Criteria in Solid Tumors [RECIST] version 1.114 
or by bone scan as per PCWG2 criteria); a castrate 
testosterone concentration of less than 50 ng/dL; an 
Eastern Cooperative Oncology Group (ECOG) perfor­
mance status of 2 or less; and adequate organ function 
(including haemoglobin ≥9 g/dL after a protocol amend­
ment on March 15, 2018 [previously ≥10 g/dL], platelets 
≥100 × 10⁹ per L, serum creatinine ≤1·5 times the institu­
tional upper limit of normal, and albumin >25 g/L). 
Patients previously treated with PARP inhibitors, 
platinum, cyclophosphamide, or mito xantrone were not 
eligible, nor were patients with known symptomatic 
brain metastasis or untreated spinal cord compressions. 
The baseline count for circulating tumour cells 
(CellSearch system; Menarini Silicon Biosystems, Castel 
Maggiore, Italy) had to be five cells per 7·5 mL blood or 
higher except in patients with radiologically measurable 
target lesions of 2 cm or more in diameter on the baseline 
CT scan and a PSA concentration of 2 ng/mL or higher 
on screening. The full eligibility criteria are in the 
appendix (pp 3–4). The complete study protocol is 
available in the appendix.
The study was approved by the London–Surrey Borders 
Research Ethics Committee (REC reference 11/LO/2019), 
and co­sponsored by The Royal Marsden NHS 
Foundation Trust and The Institute of Cancer Research 
(ICR), London, UK. The trial was done in accordance 
with the principles of good clinical practice and overseen 
by independent data monitoring and trial steering 
committees. A trial management group was responsible 
for the day­to­day running of the trial. The Clinical Trials 
and Statistics Unit at ICR (ICR­CTSU) had overall 
responsibility for trial coordination, monitoring, and 
analysis. Patients provided written informed consent 
before enrolment, both for the NGS prescreening and 
treatment stages.
Randomisation and masking
Eligible patients were randomly allocated (1:1) to receive 
olaparib at 300 mg (approved dose for the tablet 
formulation in ovarian and breast cancer15) or 400 mg 
twice a day. Randomisation was done centrally by the 
ICR­CTSU via telephone. The allocation sequence was 
generated centrally by a computer­generated mini­
misation algorithm derived by the ICR­CTSU, with 
circulating tumour cell count at screening (≥5 cells per 
7·5 mL blood vs <5 cells per 7·5 mL blood) as a balancing 
factor. ICR­CTSU staff involved in the randomisation 
were not involved in the clinical running of the trial or 
data collection. Neither participants nor clinicians were 
masked to dose allocation.
Procedures
The targeted NGS of tumour samples was done at the 
Cancer Biomarkers Laboratory at ICR. DNA was extracted 
from formalin­fixed and paraffin­embedded (FFPE) 
tumour blocks with a DNA FFPE Tissue Kit (Qiagen, 
Hilden, Germany). Samples that passed quality control 
testing with an FFPE QC Kit (Illumina, San Diego, CA, 
USA) were used for library preparation with a customised 
panel (GeneRead DNAseq Mix­n­Match Panel V2; 
Qiagen) covering 113 genes; libraries were read with a 
MiSeq Sequencer (Illumina). Further details on the 
sample processing, quality control, bioinformatics 
pipelines, and panel design are available in the appendix 
(pp 5–7).16 Patients previously known to have germline 
aberrations were eligible only on confirmatory tumour 
testing by NGS.
All patients received oral olaparib (300 mg or 
400 mg, tablet formulation) twice daily continuously in 
4­week cycles until evidence of radiographic progression 
(based on RECIST 1.1 for soft tissue disease, or the 
appearance of ≥2 lesions on bone scan), unacceptable 
toxicity according to investigator review, or patient 
decision to discontinue. Discontinuation because of 
clinical progression was the decision of the treating 
physician; discontinuation based solely on rising PSA in 
the absence of radiographic or clinical progression was 
discouraged. Patients treated with 300 mg twice daily 
were offered the option of dose escalation to 400 mg 
twice daily on confirmation of radiographic progression, 
providing the escalation was considered to be clinically 
indicated by the treating physician and the patient had 
not previously required a dose reduction for management 
of toxicity.
Clinical assessments, including reviews of adverse 
events (according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events 
[CTCAE] version 4.02) and ECOG performance status, 
physical examination, and routine blood tests 
(haematology and biochemistry), took place 2 weeks after 
the start of treatment, and then at the start of every new 
4­week cycle. Radiological assessments (CT and bone 
scans) were done every 12 weeks. Local radiological 
response assessments were used for the primary 
endpoint definition; all RECIST 1.1 responses were 
confirmed by central review by radiologists at ICR 
(AC and NT). Circulating tumour cell counts were 
measured every cycle for the first 12 weeks, and thereafter 
every 12 weeks. Circulating tumour cell counts were 
centrally analysed at the Cancer Biomarkers Laboratory 
at ICR (by PF, BE, and GF) and results were not made 
available to the treating physician. PSA serum measure­
ments were collected every cycle if available, and every 
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12 weeks at a minimum. Blood samples for correlative 
biomarker studies were taken every 4 weeks. Repeated 
tumour biopsies were optional, and pursued when 
feasible at baseline, after 1–4 weeks on therapy, and at the 
time of progression. Guidance on drug interruptions or 
dose reductions for CTCAE grade 3–4 haematological 
and non­haematological toxicities were implemented as 
outlined in the protocol. Up to 42 days of temporary 
interruption of treatment was allowed prior to mandating 
permanent discontinuation.
Outcomes
The primary endpoint was confirmed response, defined 
as a composite of any of the following outcomes: 
radiological objective response (as assessed by RECIST 
1.1 [modified with PCWG2 recommendations], a decrease 
in PSA of 50% or more (PSA50) from baseline, and 
conversion of circulating tumour cell count (from ≥5 cells 
per 7·5 mL blood at baseline to <5 cells per 7·5 mL 
blood17). To be judged a response confirmation in a 
second consecutive assessment at least 4 weeks later was 
required.
Secondary endpoints were: radiographic progression­
free survival, defined as the time from randomisation to 
first evidence of radiographic progression (according to 
RECIST 1.1 or bone scan as per PCWG2 criteria) or 
death; time to radiographic progression, defined as the 
time from randomisation to first evidence of radiographic 
progression; progression­free survival, defined as the 
time from randomisation to radiographic progression, 
unequivocal clinical pro gression, or death; overall 
survival, defined as the time from randomisation to 
death from any cause; time to PSA progression, defined 
as a confirmed increase of 25% or more and an absolute 
increase of 2 ng/mL or more in PSA from the nadir 
(PCWG2); duration of PSA response, defined as the time 
from the first documented PSA decrease of 50% or 
greater to PSA progression; best percentage change in 
PSA from baseline while on treatment; percentage 
change in PSA from baseline at 12 weeks (or earlier if 
therapy was discontinued); proportion of patients with 
circulating tumour cell count conversion; and the safety 
and tolerability profile of olaparib.
A prespecified exploratory endpoint was response 
in patients in whom dose was escalated to 400 mg 
twice daily after progression on 300 mg twice daily. A 
pharma cokinetics sub­study was planned but because of 
patients declining recruitment it was closed prematurely 
with no analyses pursued.
Statistical analysis
This trial followed a selection (or pick­the­winner) 
design.18 Each dose cohort was assessed independently 
for the primary endpoint. The sample size needed to 
show the minimum desired antitumour activity was 
determined on the basis of A’Hern’s one­stage design, 
with a response of 30% or less for the null hypothesis, 
and a response of more than 50% for the alternative 
hypothesis (one­sided α level of 0·05 and a β level 
of 0·15). Following the A’Hern design, if at least 19 (43%) 
of 44 evaluable patients in a dose cohort responded, then 
the dose cohort would be considered successful. If the 
400 mg twice daily dose cohort was deemed successful, 
the DDR biomarker identified in TOPARP­A, in which 
all patients received 400 mg twice daily, would be 
considered validated as being predictive of response. In 
the event of both dose cohorts being successful, the pick­
the­winner selection strategy would include consideration 
of secondary end points. No formal interim analyses were 
planned.
For the primary endpoint, the evaluable population was 
defined as all randomly assigned patients who met all of 
the eligibility criteria and commenced trial treatment, 
unless they discontinued treatment prior to 12 weeks 
for reasons that were not related to the study drug or 
disease. Sensitivity analyses of the primary endpoint 
were done in the intention­to­treat (ITT) population (all 
randomly assigned patients) and per protocol population 
(all evaluable patients who received at least one cycle of 
olaparib and had no eligibility violations). A post­hoc 
sensitivity analysis in patients with a circulating tumour 
cell count of five or more cells per 7·5 mL blood at 
baseline was done for comparison with TOPARP­A 
results. All other efficacy analyses were done in the ITT 
population. Toxicity was analysed in all patients who 
received at least one dose of olaparib, and the worst 
grades of adverse events that occurred during treatment 
for each dose cohort are reported. Serious adverse events 
and deaths observed within 30 days of the last dose of 
study treatment were summarised by dose cohort, as well 
as the exposure to study drug and reasons for discon­
tinuation, dose modification or interruption, and 
treatment delay.
Analysis of the primary endpoint was triggered when 
all patients had completed at least 6 months of treat­
ment (in the absence of prior discontinuation). 
Evaluable patients who discontinued treatment prior to 
12 weeks due to progression or toxicity and had no follow­
up assessments for the primary endpoint were 
considered non­responders. Response is presented along 
with exact two­sided 95% CIs. Percentage changes from 
baseline in PSA concentration and the sum of target 
lesions (RECIST 1.1) are represented in waterfall plots. 
Time­to­event endpoints are summarised by Kaplan­
Meier curves, and median times estimated with 
95% CIs. For radiographic progression­free survival and 
progression­free survival, patients alive and without 
progression were censored at the last scheduled disease 
assessment during the study. For time to radiographic 
progression, patients who did not progress radiologically 
were censored at the last scheduled disease assessment 
during the study or date of death, whichever occurred 
first. Patients alive at the end of follow­up were censored 
for the analysis of overall survival. Landmark analyses 
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A
119 patients in whom screening not possible
30 without samples for testing
89 with samples that failed quality assessment 
       or had insufficient tumour tissue
431 patients without DDR gene aberrations
 
 
 
161 patients with any DDR gene aberration  
98 patients randomly assigned
63 patients not randomly assigned
41 ineligible
10 due to patient or clinical decision
12 died during pre-screening
46 evaluable for analysis of the primary endpoint
3 patients became ineligible
2 used prohibited medication ≤30 days
 before starting olaparib
1 CTC count <5 cells per 7·5 mL 
blood and target lesion <2 cm 
711 patients registered for molecular screening 
49 patients allocated to 300 mg dose (intention-to-treat population)
 DDR gene aberration subgroups*:
 15 BRCA1/2
 10 ATM
 15 CDK12
 3 PALB2
 10 other
49 patients allocated to 400 mg dose (intention-to-treat population)
 DDR gene aberration subgroups:
 17 BRCA1/2
 11 ATM
 6 CDK12
 4 PALB2
 11 other
46 evaluable for analysis of the primary endpoint
3 patients became ineligible
3 CTC count <5 cells per 7·5 mL 
blood and target lesion <2 cm  
BRCA2†
BRCA1
ATM
CDK12
PALB2
ARID1A
ATRX
CHEK1
CHEK2
FANCA
FANCF
FANCG
FANCI
FANCM
MSH2
NBN
RAD50
WRN
31%
2%
21%
21%
7%
1%
1%
1%
5%
5%
2%
1%
1%
2%
1%
1%
1%
7% * ** *
*
*
**
*
* * ** * *
*
* * * * *
* ** * * * * * * * * * *
Genetic alteration
Inframe mutation (putative driver)
Missense mutation (putative driver)
Truncating mutation (unknown clinical
 significance)
Homozygous deletion
No alterations
Germline 
mutation
Truncating mutation (putative driver)
Missense mutation 
(unknown clinical
significance)
*
B
Figure 1: (A) Trial profile and 
(B) DDR gene alterations in 
the intention-to-treat 
population (n=98)
DDR=DNA damage response. 
CTC=circulating tumour cell. 
*Non-mutually exclusive 
subgroups: one patient had 
BRCA1/2, CDK12, and other 
mutations, and two patients 
had both PALB2 and other 
mutations (included in each 
subgroup). †The BRCA2 
K3226* variant is supposedly 
non-pathogenic19 and was 
therefore not considered 
sufficient for patients to be 
considered eligible; however, 
one patient with a BRCA2 
K3226* variant was included 
because of evidence of 
concomitant loss of the 
contralateral allele.
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were used to explore the association between circulating 
tumour cell conversion at 8 weeks and 12 weeks with 
radiographic progression­free survival and overall 
survival. Additionally, exploratory subgroup analyses 
according to different genes of interest were preplanned 
for the efficacy endpoints. Five non­mutually exclusive 
subgroups were predefined: patients with alterations in 
BRCA1/2, ATM, CDK12, PALB2, and any other gene 
related to DDR or associated with PARP inhibitor 
sensitivity. Patients who had more than one DDR gene 
aberration were included in the analysis of all relevant 
subgroups.
The trial was not powered for head­to­head direct 
comparisons of the two dose cohorts, and so tests to 
compare them were considered hypothesis­generating 
(ie, χ² test to compare the proportion of patients with a 
response and log­rank test to compare Kaplan­Meier 
curves). Statistical analyses were done with Stata software 
(version 15), on a snapshot of the data taken on 
July 5, 2019. The statistical analysis plan is available in 
the appendix.
This trial is registered with ClinicalTrials.gov, 
NCT01682772 and on the European Clinical Trials 
database, EudraCT 2011–000601–49.
Role of the funding source
The funders had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author 
had full access to all data in the study and had 
final responsibility for the decision to submit for 
publication.
Results
Between April 1, 2015 and Aug 30, 2018, 711 patients 
consented to NGS prescreening (figure 1A). For 
30 (4%) patients, no samples were made available for 
testing. From 681 patients with at least one sample 
available, 779 tumour samples were analysed (637 [82%] 
primary tumour samples and 142 [18%] post­castration­
resistance metastatic biopsies). For 89 (13%) patients, 
biomarker determination was not possible because of the 
300 mg dose 
group (n=49)
400 mg dose 
group (n=49)
Age at trial entry 67·3 
(61·2–72·1)
67·6 
(63·2–72·7)
Years from initial diagnosis 3·5 (2·4–6·4) 5·2 (3·6–7·3)
Years from diagnosis of 
castration-resistant prostate cancer
2·4 (1·2–3·7) 3·0 (1·8–4·0)
Metastatic disease at diagnosis
Yes 24 (49%) 25 (51%)
No 24 (49%) 21 (43%)
Not available 1 (2%) 3 (6%)
Gleason score at diagnosis
≤7 4 (8%) 15 (31%)
≥8 42 (86%) 29 (59%)
Not available 3 (6%) 5 (10%)
Previous treatment for prostate cancer
Prostatectomy 7 (14%) 6 (12%)
Radical radiotherapy 22 (45%) 21 (43%)
Bisphosphonates 2 (4%) 2 (4%)
Radium-223 6 (12%) 8 (16%)
Docetaxel 49 (100%) 49 (100%)
Cabazitaxel 15 (31%) 22 (45%)
Abiraterone acetate 24 (49%) 22 (45%)
Enzalutamide 27 (55%) 29 (59%)
Abiraterone acetate or 
enzalutamide or both
43 (88%) 45 (92%)
Evidence of progression at trial entry
PSA only 15 (31%) 12 (24%)
Radiographic progression (with or 
without PSA progression)
34 (69%) 37 (76%)
Site of metastatic disease at trial entry*
Lung 4 (8%) 4 (8%)
Lymph nodes 34 (69%) 32 (65%)
Liver 11 (22%) 12 (24%)
Bone 41 (84%) 41 (84%)
PSA at trial entry, ng/mL 151·5 
(49·0–446·0)
158·0 
(45·5–472·0)
(Table 1 continues in next column)
300 mg dose 
group 
(n=49)
400 mg dose 
group 
(n=49)
(Continued from previous column)
CTC count per 7·5 mL blood at trial entry
<5 17 (35%) 17 (35%)
≥5 31 (63%) 32 (65%)
Not available† 1 (2%) 0
RECIST 1·1 soft tissue disease
Bone lesions only 5 (10%) 5 (10%)
Non-measurable disease (with or 
without bone lesions)
5 (10%) 8 (16%)
Measurable disease (with or 
without bone lesions)
39 (80%) 36 (73%)
DNA damage response gene aberration subgroup‡
BRCA1/2 15 (31%) 17 (35%)
ATM 10 (20%) 11 (22%)
CDK12 15 (31%) 6 (12%)
PALB2 3 (6%) 4 (8%)
Other 10 (20%) 11 (22%)
Data are median (IQR) or n (%). Percentages might not add up to 100% due to 
rounding. PSA=prostate-specific antigen. CTC=circulating tumour cell. 
RECIST=Response Evaluation Criteria in Solid Tumors. *More than one site could 
be reported. †Assessment of CTC count at screening not possible due to CTC kit 
shortage; the patient was allowed to be randomly assigned as he had RECIST 1·1 
measurable disease; for randomisation CTC count was assumed to be <5 cells per 
7·5 mL blood but the patient was unevaluable for CTC response. ‡Non-mutually 
exclusive subgroups: one patient in the 300 mg cohort had BRCA1/2, CDK12, and 
other mutations, and two patients in the 300 mg cohort had PALB2 and other 
mutations (in MSH2 and NBN, respectively).
Table 1: Baseline characteristics of patients in the intention-to-treat 
population
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sample or the sequencing data not fulfilling quality 
control parameters.
Of the 592 patients with evaluable tissue samples, 
161 (27%) had DDR gene aberrations on the basis of 
NGS. An oncoprint summarising all alterations detected 
during prescreening is presented in the (p 14). The most 
commonly detected DDR gene aberrations were 
mutations or homozygous deletions in BRCA2 (44 [7%] of 
the 592 patients), ATM (40 [7%]), and CDK12 (33 [6%]).
98 patients with DDR gene aberrations were randomly 
assigned and treated in the two dose cohorts (49 patients in 
each cohort). At the time of the data snapshot, two patients 
remained on olaparib treatment. A greater number of 
participants were recruited than originally planned, at the 
recommendation of the independent data monitoring 
committee, to account for six participants (three in each 
cohort) who were deemed not evaluable (ineligible post­
randomisation) for the primary end point analyses. Median 
follow­up was 24·8 months (IQR 16·7–35·9).
The baseline characteristics of all patients assigned to 
a dose cohort are shown in table 1. All patients had 
previously received docetaxel, and 88 (90%) had also 
been treated with one or both of abiraterone acetate and 
enzalutamide prior to study entry. The distribution of 
gene aberration subgroups was largely similar between 
the two dose cohorts, except for CDK12 alterations 
(table 1). The composition of the prespecified gene 
aberration subgroups in the intention­to­treat popu­
lation are shown in figure 1B. Baseline features of 
each gene aberration subgroup are summarised in the 
appendix (p 8).
92 patients (46 in each dose cohort) were evaluable for 
the primary endpoint. 70 (76%) patients were evaluable 
for the RECIST 1.1 response, 89 (97%) for PSA response, 
and 55 (60%) for circulating tumour cell conversion. 
A confirmed com posite response was observed in 
25 (54·3%; 95% CI 39·0–69·1) of 46 patients in the 
400 mg cohort and 18 (39·1%; 25·1–54·6) of 46 patients 
in the 300 mg cohort (p=0·14; table 2). Radiological 
response according to RECIST 1.1 was observed in eight 
(24·2%; 95% CI 11·1–42·3) of 33 evaluable patients in 
the 400 mg cohort and six (16·2%; 6·2–32·0) of 37 in the 
300 mg cohort; PSA50 response was observed in 
17 (37·0%; 23·2–52·5) of 46 and 13 (30·2%; 17·2–46·1) of 
43, respectively; and circulating tumour cell count 
conversion was observed in 15 (53·6%; 33·9–72·5) of 
28 and 13 (48·1%; 28·7–68·1) of 27, respectively. Based 
on the first 44 evaluable patients included in each cohort 
(as planned initially), 25 (57%) confirmed responses were 
recorded in the 400 mg cohort and 18 (41%) in the 300 mg 
cohort; thus, the predefined criteria for success was met 
for the 400 mg regimen but not for the 300 mg regimen.
When including in the analysis only the 55 evalu able 
patients with a circulating tumour cell count of ≥5 cells 
per 7·5 mL blood at baseline, confirmed composite 
response was observed in 17 (60·7%; 95% CI 40·6–78·5) 
of 28 evaluable patients in the 400 mg cohort and 13 
(48·1%; 28·7–68·1) of 27 in the 300 mg cohort (appendix 
p 9). In keeping with previous reports,17,20 circulating 
tumour cell conversions post­treatment were significantly 
associated with longer radiographic progression­free 
survival and overall survival in landmark analyses 
(appendix p 15).
The best percentage change from baseline in PSA 
concentration and in the sum of target lesions in 
each patient in the intention­to­treat population are pre­
sented in figure 2A and 2B. At the time of analysis, 
45 (92%) of 49 patients on 400 mg olaparib and 
46 (94%) of 49 patients on 300 mg olaparib had radio­
graphic progression or died; median radiographic 
progression­free survival was 5·5 months (95% CI 
4·4–8·3) in the 400 mg cohort and 5·6 months (3·7–7·7) 
in the 300 mg cohort (figure 2C). 39 (80%) patients on 
400 mg and 38 (78%) patients on 300 mg had died, with a 
median overall survival of 14·3 months (9·7–18·9) in the 
400 mg cohort and 10·1 months (9·0–17·7) in the 300 mg 
cohort. Further results on the secondary endpoints are 
sum marised in the appendix (pp 16–18). The time on 
Composite overall response RECIST 1.1 objective response PSA50 response CTC conversion RECIST 1.1 or PSA50 response
Total 43/92 (46·7%; 36·3–57·4) 14/70 (20·0%; 11·4–31·3) 30/89 (33·7%; 24·0–44·5) 28/55 (50·9%; 37·1–64·6) 32/92 (34·8%; 25·1–45·4)
By dose cohort
300 mg 18/46 (39·1%; 25·1–54·6) 6/37 (16·2%; 6·2–32·0) 13/43 (30·2%; 17·2–46·1) 13/27 (48·1%; 28·7–68·1) 13/46 (28·3%; 16·0–43·5)
400 mg 25/46 (54·3%; 39·0–69·1) 8/33 (24·2%; 11·1–42·3) 17/46 (37·0%; 23·2–52·5) 15/28 (53·6% ; 33·9–72·5) 19/46 (41·3%; 27·0–56·8)
By gene subgroup*
BRCA1/2 25/30 (83·3%; 65·3–94·4) 11/21 (52·4%; 29·8–74·3) 23/30 (76·7%; 57·7–90·1) 17/22 (77·3%; 54·6–92·2) 24/30 (80·0%; 61·4–92·3)
ATM 7/19 (36·8%; 16·3–61·6) 1/12 (8·3%; 0·2–38·5) 1/19 (5·3%; 0·1–26·0) 5/10 (50·0%; 18·7–81·3) 2/19 (10·5%; 1·3–33·1)
CDK12 5/20 (25·0%; 8·7–49·1) 0/18 (0·0%; 0–18·5†) 0/20 (0·0%; 0–16·8†) 5/12 (41·7%; 15·2–72·3) 0/20 (0·0%; 0–16·8†)
PALB2 4/7 (57·1%; 18·4–90·1) 2/6 (33·3%; 4·3–77·7) 4/6 (66·7%; 22·3–95·7) 0/2 (0–84·2†) 4/7 (57·1%; 18·4–90·1)
Other 4/20 (20·0%; 5·7–43·7) 0/17 (0·0%; 0–19·5†) 2/17 (11·8%; 1·5–36·4) 3/11 (27·3%; 6·0–61·0) 2/20 (10·0%; 1·2–31·7)
Data are n/N (%; 95% CI), where n=responding patients and N=evaluable patients. PSA50 response=PSA decrease ≥50%. RECIST=Response Evaluation Criteria in Solid Tumors. PSA=prostate-specific antigen. 
CTC=circulating tumour cell. *Non-mutually exclusive subgroups: one patient treated at 300 mg had BRCA1/2, CDK12, and other mutations, and two patients treated at 300 mg had both PALB2 and other 
mutations. These patients have been included in analysis for each subgroup separately (for the gene subgroup analyses, dose cohorts have been pooled). †One-sided exact binomial 95% confidence intervals.
Table 2: Overall antitumour activity of olaparib in patients with DNA damage response gene aberrations by dose cohort and gene subgroup
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treatment for each patient is represented in figure 2D. A 
summary of treatment dose reductions, escalations 
(300 mg cohort), interruptions, and discontinuations in 
each dose cohort is presented in the appendix (p 10).
Dose escalation from 300 mg to 400 mg was pursued in 
11 patients. At the time of the data snapshot, ten had 
discontinued treatment: two due to adverse events and 
eight due to disease progression. These 11 patients were 
on treatment with 400 mg olaparib for a median of 
7·8 weeks (IQR 3·7–10·4). None of these patients 
achieved a response after dose escalation.
The confirmed composite response, and response by 
individual components, for each of the predefined gene 
subgroups are shown in table 2. Further analysis of 
secondary endpoints per gene subgroup are presented in 
figure 3 and the appendix (pp 11–14, 19). The BRCA1/2 
subgroup had the highest number of responses both for 
the composite endpoint of confirmed response and across 
all its component outcomes (table 2) and the longest 
median radiographic progression­free survival (figure 3C) 
of all DDR gene aberration subgroups. Of the 32 patients 
in the BRCA1/2 subgroup, 13 had germline mutations in 
BRCA2, six somatic mutations in BRCA2, 11 homozygous 
deletions in BRCA2, and the remaining two cases had 
mutations in BRCA1 (one germline and one somatic). 
Ten patients in the BRCA1/2 subgroup (five allocated to 
400 mg and five to 300 mg) remained on treatment for 
more than 1 year.
21 patients with suspected deleterious ATM aber rations 
were treated (table 1; one patient with homozygous 
deletion and the rest with germline or somatic mutations 
that are predicted to result in either truncation or 
missense mutations affecting the kinase domain), and 19 
were evaluable for response (table 2). Details of each 
component of response in the evaluable patients with 
ATM aberrations are shown in the appendix (p 12).
No confirmed PSA50 or RECIST responses were 
observed in the 20 evaluable patients in the CDK12 
subgroup (table 2), although five patients achieved CTC 
conversion (including one with concomitant BRCA1/2 
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Figure 2: Antitumour activity by allocated dose cohort (intention-to-treat population)
(A) Best percentage change from baseline in PSA during treatment. (B) Best percentage change from baseline in the sum of target lesions (Response Evaluation Criteria in Solid Tumors 1·1) during 
treatment. (C) Radiographic progression-free survival. (D) Swimmers plot of time on treatment for each patient, indicating periods of treatment interruptions, dose reductions, and, in the 300 mg 
cohort, dose escalations. Treatment periods of ≥6 months and ≥12 months are highlighted. PSA=prostate-specific antigen. PSA50=decrease in prostate-specific antigen of ≥50%.
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alteration; appendix p 13). Conversely, four of seven 
patients with PALB2 mutations responded to treatment 
(table 2).
20 patients were evaluated in the subgroup with other 
gene alterations associated with DDR or PARP inhibitor 
sensitivity (table 2). PSA50 responses were seen in 
two patients: one with a somatic nonsense mutation in 
FANCA and one with a CHEK2 mutation.
The safety population included all 98 patients treated 
(table 3). The tolerability profile was in line with what 
has been previously reported for olaparib and other 
PARP inhibitors.21–23 The most common grade 3–4 
adverse event in both cohorts was anaemia (15 [31%] in 
the 300 mg cohort and 18 [37%] in the 400 mg cohort).
18 (37%) patients in the 400 mg cohort and six (12%) 
in the 300 mg cohort required at least one dose 
reduction (appendix p 10), with anaemia being the most 
common adverse event leading to dose reductions 
(two patients in the 300 mg cohort and nine in the 
400 mg cohort). Eight patients who achieved a response 
on 400 mg continued to respond for more than 
6 months after dose reduction to 300 mg or lower. 
Overall, 18 (19%) of the 98 patients were permanently 
discontinued from olaparib treatment due to adverse 
events (appendix p 10) The most common adverse 
events leading to discon tinuation were anaemia (two of 
five patients who discontinued on 400 mg and five of 
13 on 300 mg) and fatigue (three on 400 mg and four on 
300 mg).
107 serious adverse events were reported in 
49 (50%) patients (300 mg cohort: 49 events in 22 patients; 
400 mg cohort: 58 events in 24 patients) with 19 serious 
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Figure 3: Antitumour activity by gene aberration subgroup (intention-to-treat population, pooled 300 mg and 400 mg cohorts)
(A) Maximum percentage change from baseline in PSA during treatment. (B) Maximum percentage change from baseline in the sum of target lesions (Response Evaluation Criteria in Solid Tumors 1·1) 
during treatment. (C) Radiographic progression-free survival. (D) Swimmers plot of time on treatment for each patient. ITT=intention-to-treat. NE=not estimable. PSA=prostate-specific antigen. 
PSA50=decrease in prostate-specific antigen of ≥50%. *Patients presenting with mutliple mutations are represented in a single subgroup.
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adverse reactions (possibly related to study drug; 11 in the 
300 mg cohort and eight in the 400 mg cohort) in 
13 patients (8 patients in the 300 mg cohort and 5 in the 
400 mg cohort). The most common serious adverse 
reaction was anaemia (occurring in six patients in the 
300 mg cohort and five patients in the 400 mg cohort). 
Four serious adverse reactions were considered suspected 
unexpected, two in each dose cohort group. In the 
400 mg cohort, one patient had community­acquired 
pneumonia, and the same patient had atrial fibrillation 
with myocardial infarction (recovering from both events). 
In the 300 mg cohort, one patient was diagnosed with 
myelodysplasia after 6·5 months of treatment, and 
developed acute myeloid leukaemia after olaparib 
discontinuation. One patient on 300 mg olaparib died 
due to a myocardial infarction (table 3), assessed as 
possibly drug­related, after 11 days of treatment. All other 
deaths were unrelated to treatment (n=76; 70 due to 
disease and six due to other causes).
Discussion
The TOPARP­B trial has confirmed the antitumour 
activity of olaparib against metastatic castration­resistant 
prostate cancer with specific DDR gene aberrations. The 
number of composite responses observed in the cohort 
of patients who received 400 mg tablets of olaparib twice 
daily met the predefined criteria for success, validating 
the DDR biomarker identified in TOPARP­A as being 
predictive of response.12 Overall, the data suggest that 
both drug dose and the specific type of DDR gene 
aberration might influence antitumour activity, given 
that the composite response at the 300 mg regimen was 
lower and did not reach the predefined criteria for 
success. The antitumour activity observed varied 
considerably for different DDR gene aberrations, with 
the greatest antitumour activity seen in the subgroup 
with BRCA1/2 alterations.
Despite randomisation, CDK12 aberrations were 
imbalanced between the cohorts, with an enrichment in 
the 300 mg cohort. This imbalance might explain, at least 
in part, the inferior composite response in the 300 mg 
cohort.4,24 The rationale to explore the two doses 
originated from prior clinical observations indicating a 
dose–response relationship for olaparib between 100 mg 
and 400 mg at twice daily dosing, although 400 mg has 
been associated with enhanced toxicity.25,26 In keeping 
with this finding, 37% patients at 400 mg had to reduce 
their dose to 300 mg, most commonly because of 
anaemia. All of these data would need to be considered 
when assessing the optimal dose of olaparib for prostate 
cancer treatment.
Our results support the implementation of routine 
genomic testing of metastatic prostate cancer, to detect 
DNA repair defects for targeting by PARP inhibition. In 
a previous study, we reported an enrichment of germline 
inherited mutations in DDR genes in metastatic prostate 
cancer,27 which has led to the recommendation of broad 
300 mg (n=49) 400 mg (n=49)
Grade 1–2 Grade 3 Grade 4 Grade 1–2 Grade 3 Grade 4
Anaemia 16 (33%) 14 (29%) 1 (2%) 19 (39%) 18 (37%) 0
Fatigue 19 (39%) 3 (6%) 0 27 (55%) 4 (8%) 0
Back pain 13 (27%) 4 (8%) 0 11 (22%) 3 (6%) 0
Nausea 17 (35%) 1 (2%) 0 13 (27%) 0 0
Platelet count decreased 9 (18%) 2 (4%) 1 (2%) 12 (24%) 3 (6%) 0
Decreased appetite 13 (27%) 2 (4%) 0 10 (20%) 0 0
Vomiting 10 (20%) 0 0 15 (31%) 0 0
Weight decreased 9 (18%) 1 (2%) 0 15 (31%) 0 0
Diarrhoea 8 (16%) 1 (2%) 0 10 (20%) 1 (2%) 0
Arthralgia 8 (16%) 1 (2%) 0 5 (10%) 4 (8%) 0
Hypertension 9 (18%) 1 (2%) 0 4 (8%) 4 (8%) 0
Neutrophil count decreased 9 (18%) 2 (4%) 0 4 (8%) 2 (4%) 1 (2%)
Dyspnoea 5 (10%) 1 (2%) 0 10 (20%) 1 (2%) 0
Abdominal pain 4 (8%) 0 0 6 (12%) 5 (10%) 1 (2%)
Blood creatinine increased 9 (18%) 0 0 6 (12%) 0 0
Oedema peripheral 6 (12%) 0 0 8 (16%) 1 (2%) 0
Urinary tract infection 3 (6%) 3 (6%) 0 6 (12%) 3 (6%) 0
Constipation 7 (14%) 0 0 7 (14%) 0 0
Cough 3 (6%) 0 0 9 (18%) 0 0
Musculoskeletal chest pain 3 (6%) 0 0 9 (18%) 0 0
Musculoskeletal pain 5 (10%) 1 (2%) 0 5 (10%) 1 (2%) 0
Hypokalaemia 3 (6%) 0 0 8 (16%) 0 0
Muscular weakness 4 (8%) 0 0 5 (10%) 2 (4%) 0
White blood cell count decreased 4 (8%) 0 0 6 (12%) 1 (2%) 0
Aspartate aminotransferase 
increased
3 (6%) 0 1 (2%) 4 (8%) 1 (2%) 0
Alkaline phosphatase increased 3 (6%) 0 0 5 (10%) 1 (2%) 0
Dysgeusia 6 (12%) 0 0 3 (6%) 0 0
Haematuria 5 (10%) 0 0 2 (4%) 2 (4%) 0
Influenza like illness 3 (6%) 0 0 6 (12%) 0 0
Muscle spasms 3 (6%) 0 0 6 (12%) 0 0
Gamma-glutamyl transferase 
increased
3 (6%) 0 0 2 (4%) 2 (4%) 1 (2%)
Lower respiratory tract infection 4 (8%) 1 (2%) 0 2 (4%) 1 (2%) 0
Lymphocyte count decreased 2 (4%) 1 (2%) 0 3 (6%) 2 (4%) 0
Pyrexia 4 (8%) 2 (4%) 0 2 (4%) 0 0
Alanine aminotransferase increased 2 (4%) 0 0 3 (6%) 2 (4%) 0
Groin pain 3 (6%) 0 0 2 (4%) 2 (4%) 0
Dizziness 2 (4%) 1 (2%) 0 2 (4%) 1 (2%) 0
Spinal cord compression 0 1 (2%) 0 0 5 (10%) 0
Blood bilirubin increased 1 (2%) 0 0 3 (6%) 0 1 (2%)
Cellulitis 2 (4%) 0 0 2 (4%) 1 (2%) 0
Pain 1 (2%) 1 (2%) 0 2 (4%) 1 (2%) 0
Hydronephrosis 1 (2%) 2 (4%) 0 0 1 (2%) 0
Hyponatraemia 0 1 (2%) 0 2 (4%) 1 (2%) 0
Myocardial infarction* 0 1 (2%) 1 (2%) 0 1 (2%) 0
Acute kidney injury 1 (2%) 0 1 (2%) 1 (2%) 0 0
Hyperkalaemia 0 1 (2%) 0 2 (4%) 0 0
Rectal haemorrhage 0 1 (2%) 0 1 (2%) 1 (2%) 0
Amylase increased 0 0 0 1 (2%) 1 (2%) 0
Atrial fibrillation 0 0 0 1 (2%) 1 (2%) 0
(Table 3 continues on next page)
Articles
172 www.thelancet.com/oncology   Vol 21   January 2020
germline NGS testing in all men with metastatic prostate 
cancer per National Comprehensive Cancer Network 
guidelines. The antitumour activity of olaparib indicated 
in this trial, in patients with metastatic castration­
resistant prostate cancer with both germline and somatic 
aberrations of BRCA2, now supports the implementation 
of NGS testing of tumour samples.
Antitumour activity was also observed in other DDR 
gene aberration subgroups. Responses in tumours with 
PALB2 mutations were frequent, although the low 
prevalence of these mutations means that further data 
are required to confirm these findings. Clinical qualifi­
cation of low­prevalence biomarkers is challenging in 
the pursuit of precision medicine approaches; the valid­
ation of genomic signatures24,28 or functional biomarkers29 
that identify tumours with defective homologous­
recombination, regardless of the mutated gene of origin, 
could help move the field forward, but such assays have 
not yet been validated in prostate cancer.
Conversely, germline and somatic ATM aberrations 
are common in metastatic prostate cancer; ATM 
functions as a cell cycle checkpoint, preventing cell cycle 
progression in the presence of DNA damage rather than 
directly mediating repair, unlike BRCA2 and PALB2. In 
the TOPARP­A trial, five patients had ATM aberrations 
in tumour biopsies: two of these had a PSA response, 
and two more had circulating tumour cell conversion. 
Preliminary results suggest that rucaparib, another 
PARP inhibitor, results in few PSA decreases in patients 
with ATM aberrations.30 In TOPARP­B, we treated 
21 patients with suspected deleterious ATM aberrations: 
two achieved a RECIST or PSA response, and several 
others had circulating tumour cell count conversions 
following therapy. Circulating tumour cell count 
decreases seen in this subgroup were associated with 
increased duration on the trial, tumour shrinkage per 
RECIST, and a PSA decrease, as was the case for the 
overall TOPARP­B population, with circulating tumour 
cell conversions robustly associating with increased 
radiographic progression­free survival and overall 
survival. Overall, the data suggest that the antitumour 
activity of olaparib in metastatic castration­resistant 
prostate cancer with ATM loss is less than that for 
BRCA­altered tumours; nevertheless, a subset of patients 
with ATM-altered metastatic castration­resistant prostate 
cancer appear to derive benefit. However, detection of 
ATM alterations alone might be insufficient to identify 
these sensitive tumours. Further studies, as well as the 
study of rational drug combinations, are now needed to 
elucidate how to best evaluate and treat metastatic 
castration­resistant prostate cancer with ATM alter­
ations. Ongoing exploratory analyses from this trial will 
look to further characterise exceptional responses within 
each gene­defined subgroup to optimise patient 
stratification.
We do acknowledge limitations to this study. Although 
the use of targeted NGS facilitates the clinical imple­
mentation of patient stratification, this method might be 
insufficient to capture complex aberrations resulting in 
PARP inhibitor sensitivity. Furthermore, because 
all patients in our study had DDR gene aberrations and 
received olaparib, we are not able to fully differentiate the 
predictive value versus the prognostic effect of the gene 
aberrations in terms of survival. Randomised trials 
including patients with and without the biomarkers will 
be more able to clinically qualify putative predictive 
biomarkers.
Nonetheless, the results from TOPARP­B have overall 
driven the design and conduct of several registration 
trials of PARP inhibitors in metastatic castration­
resistant prostate cancer (NCT02987543, NCT02975934, 
and NCT03148795), which are likely to guide the clinical 
use of PARP inhibitors in metastatic prostate cancer in 
the future. Most of these studies aim to validate PARP 
300 mg (n=49) 400 mg (n=49)
Grade 1–2 Grade 3 Grade 4 Grade 1–2 Grade 3 Grade 4
(Continued from previous page)
Circulatory collapse 0 2 (4%) 0 0 0 0
Confusional state 1 (2%) 1 (2%) 0 0 0 0
Femoral neck fracture 0 1 (2%) 0 1 (2%) 0 0
Femur fracture 0 0 0 0 2 (4%) 0
Mobility decreased 1 (2%) 0 0 0 1 (2%) 0
Pneumonia 0 0 0 0 2 (4%) 0
Presyncope 1 (2%) 0 0 0 1 (2%) 0
Pulmonary embolism 0 1 (2%) 0 0 1 (2%) 0
Respiratory tract infection 1 (2%) 1 (2%) 0 0 0 0
Abdominal infection 0 1 (2%) 0 0 0 0
Acute myeloid leukaemia 0 0 1 (2%) 0 0 0
Arthritis bacterial 0 1 (2%) 0 0 0 0
Bronchitis 0 1 (2%) 0 0 0 0
Cauda equina syndrome 0 0 0 0 1 (2%) 0
Embolism 0 0 0 0 1 (2%) 0
Enterocolitis infectious 0 0 0 0 1 (2%) 0
Febrile neutropenia 0 0 0 0 1 (2%) 0
Hip fracture 0 1 (2%) 0 0 0 0
Intestinal obstruction 0 0 0 0 1 (2%) 0
Jaundice 0 0 0 0 1 (2%) 0
Neutropenic sepsis 0 0 0 0 1 (2%) 0
Pyelonephritis 0 0 0 0 1 (2%) 0
Radiculopathy 0 0 0 0 1 (2%) 0
Renal colic 0 1 (2%) 0 0 0 0
Sepsis 0 0 0 0 0 1 (2%)
Ureteric obstruction 0 1 (2%) 0 0 0 0
Urosepsis 0 1 (2%) 0 0 0 0
Vascular pseudoaneurysm 0 0 1 (2%) 0 0 0
Vision blurred 0 1 (2%) 0 0 0 0
Adverse events were graded according to Common Terminology Criteria for Adverse Events version 4.02, and coded 
according to the the Medical Dictionary for Regulatory Activities version 22.0. Any grade 1–2 event occurring in 10% or 
more of patients is reported. All grade 3 and 4 events are reported. *One death due to myocardial infarction (grade 5 
event deemed a suspected unexpected serious adverse reaction ) was reported (not included in table).
Table 3: Treatment-emergent adverse events
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inhibition as a precision medicine strategy for prostate 
cancers with DDR gene aberrations. Other studies, in 
parallel, are exploring the addition of PARP inhibitors to 
the standard­of­care drugs targeting the androgen 
receptor (NCT03732820 and NCT03395197), on the basis 
of results from a phase 2 clinical trial indicating that a 
broader target population than just patients with gene 
aberrations might benefit from these drugs.31
In conclusion, the data from TOPARP­B have 
confirmed the antitumour activity of olaparib against 
meta static prostate cancer with particular DDR gene 
aberrations. The high response observed in patients 
with metastatic castration­resistant prostate cancer with 
germline or somatic BRCA1/2 aberrations, and the 
durability of many of these responses, support the use of 
olaparib in this subpopulation. The antitumour activity 
observed against tumours with ATM, PALB2, FANCA, or 
CHEK2 aberrations suggest that PARP inhibitors might 
have a role as single drug therapies or in rational 
combinations against these other subtypes of metastatic 
prostate cancer, although further data are needed to 
precisely assess the clinical relevance of each of these 
different DDR gene aberrations in prostate cancer.
Contributors
JM, NP, SS, EH, and JSdB designed the trial. AE and PC centrally 
managed the trial and trial data. JM, NP, RJ, PF, SS, EH, SuC, and JSdB 
developed the protocol. JM, DB, UMcG, TE, RJ, IS, CR, SJ, MV, OP, SiC, 
AR, DMcL, AB, JT, PR, RC, and JSdB recruited participants. SM, IF, CB, 
BE, GF, AF, RR, and RP processed samples. JM, DB, UMcG, TE, RJ, IS, 
CR, SJ, MV, OP, SiC, AR, DMcL, AB, JT, SM, IF, CB, PF, BE, PR, GF, 
AF, RP, AC, RC, NT, SuC, and JSdB collected data. JM, SM, IF, GS, CB, 
BE, GF, AF, RR, RP, MCl, BG, MCr, DNR, WY, SuC, and JSdB did the 
translational experiments. NP and EH did the statistical analyses. SM, 
IF, GS, PF, MCl, BG, DNR, WY, and SuC analysed the translational data. 
JM, NP, GS, PF, AC, MCl, BG, MCr, DNR, NT, WY, EH, SuC, and JSdB 
interpreted the data. JM, NP, EH, SuC, and JSdB wrote the manuscript. 
JM, NP, UMcG, TE, RJ, IS, CR, SJ, MV, OP, SiC, AR, DMcL, AB, SM, 
AE, PC, EH, and JSdB are members of the Trial Management Group of 
TOPARP. JSdB was the chief investigator. All authors reviewed the 
manuscript prior to submission.
Declaration of interests
JM reports a grant from AstraZeneca during the conduct of the study. 
He also reports personal fees and non­financial support from 
AstraZeneca, and personal fees from Janssen Pharmaceutica, Amgen, 
and Roche, outside of the submitted work. TE reports Janssen 
Educational Grants, outside of the submitted work. RJ reports grants 
and personal fees from Astellas, AstraZeneca, Exelixis, and Roche; 
personal fees and non­financial support from Bristol­Myers Squibb, 
Janssen Pharmaceutica, Ipsen, and Merck Sharp & Dohme; grants, 
personal fees, and non­financial support from Bayer; and personal fees 
from Merck Serono, Novartis, Pfizer, Sanofi Genzyme, and EUSA, 
outside of the submitted work. CR reports non­financial support from 
Pfizer and Ipsen, and personal fees and non­financial support from 
Bristol­Myers Squibb and Eisai, outside of the submitted work. 
SJ reports personal fees from Astellas, Janssen Pharmaceutica, Bayer, 
Boston Scientific, Movember, and Almac Diagnostics, outside of the 
submitted work. MV reports non­financial support from Janssen 
Pharmaceutica and Merck Sharp & Dohme, outside of the submitted 
work. SiC reports personal fees from Bayer and Janssen Pharmaceutica, 
and grants from AstraZeneca, Clovis Oncology, Roche, and Astex 
Pharmaceuticals, outside of the submitted work. AB reports advisory 
board fees and speaker fees from Sanofi and Bayer, advisory board fees 
from Astellas, speaker fees from Janssen Pharmaceutica, 
Merck Sharp & Dohme, and Roche, and provision of educational support 
to Janssen Pharmaceutica, outside of the submitted work. PC reports 
grants from AstraZeneca during the conduct of the study. SS reports 
grants and consultancy honoraria from Bristol­Myers Squibb, 
Merck Sharp & Dohme, and Roche, and grants from Endocyte and 
AstraZeneca, outside of the submitted work. EH reports grants from 
Cancer Research UK and grants and non­financial support from 
AstraZeneca, during the conduct of the study. She also reports grants 
and non­financial support from Merck Sharp & Dohme, AstraZeneca, 
and Bayer; and grants from Janssen Pharmaceutica, Kyowa Kirin, 
Alliance Pharma, Sanofi, and Accuray, outside of the submitted work. 
JSdB reports grants from AstraZeneca during the conduct of the study. 
He also reports personal fees and non­financial support from Astellas 
Pharma, Sanofi, and Menarini Silicon Biosystems; grants, personal fees, 
and non­financial support from AstraZeneca, Daiichi, Sierra Oncology, 
and CellCentric; personal fees from Genentech, Pfizer, Bayer, 
Boehringer Ingelheim, Merck Serono, and Merck Sharp & Dohme; and 
non­financial support from Genmab, GlaxoSmithKline, Orion Pharma, 
Qiagen, Taiho Pharmaceutical, and Vertex, outside of the submitted 
work. JSdB has an Abiraterone Rewards to Inventors patent with 
royalties paid to The Institute of Cancer Research (ICR; London, UK), 
and a PARP inhibitors and DNA repair defects patent with royalties paid 
to ICR. The authors affiliated to ICR disclose that the institution is a 
joint applicant for the patent entitled DNA damage repair inhibitors for 
treatment of cancer, which includes the granted application US8143241. 
All other authors declare no competing interests.
Data sharing
The Institute of Cancer Research Clinical Trials and Statistics Unit 
(ICR­CTSU), London, UK, supports the wider dissemination of 
information from the research it does, and increased cooperation 
between investigators. Trial data is collected, managed, stored, shared, 
and archived according to ICR­CTSU standard operating procedures to 
ensure the enduring quality, integrity, and use of the data. Formal 
requests for data sharing are considered in line with ICR­CTSU 
procedures with due regard given to funder and sponsor guidelines. 
Requests are via a standard pro forma describing the nature of the 
proposed research and extent of data requirements. Data recipients are 
required to enter a formal data sharing agreement that describes the 
conditions for release and requirements for data transfer, storage, 
archiving, publication, and intellectual property. Requests are reviewed 
by the TOPARP Trial Management Group in terms of scientific merit 
and ethical considerations including patient consent. Data sharing is 
permitted if proposed projects have a sound scientific or patient benefit 
rationale as agreed by the Trial Management Group and approved by the 
ICR­CTSU independent data monitoring and steering committee as 
required. Restrictions relating to patient confidentiality and consent will 
be limited by aggregating and anonymising identifiable patient data. 
Additionally, all indirect identifiers that might lead to deductive 
disclosures will be removed in line with Cancer Research UK Data 
Sharing Guidelines.
Acknowledgments
We are grateful for the support and funding from AstraZeneca, and for 
the study grants from Cancer Research UK (CRUK/11/029, C12540/
A12829, C12540/A13230, and C12540/A20447), Prostate Cancer UK and 
the Movember Foundation through the London Movember Centre of 
Excellence (CEO13_2­002), and the Prostate Cancer Foundation 
(20131017). JM was supported by a Prostate Cancer Foundation Young 
Investigator Award (PCF­16YOUN11) and a Prostate Cancer UK 
Movember Foundation Fellowship (MRC­CRTF13­001). The Institute of 
Cancer Research (ICR) Clinical Trials and Statistics Unit (ICR­CTSU), 
London, UK, also receives programme grant funding from Cancer 
Research UK (C1491/A15955 and C1491/A25351). We also acknowledge 
support from the UK National Institute for Health Research (NIHR) 
Cancer Research Network and the UK National Health Service (NHS) 
funding to the NIHR Biomedical Research Centre at The Royal Marsden 
NHS Foundation Trust and ICR (London, UK), and support from the 
UK Experimental Cancer Medicine Centres Network. JdB is a senior 
investigator at the National Institute for Health Research (NIHR; 
London, UK). The views expressed in this article are those of the 
author(s) and not necessarily those of the UK National Health Service, 
the NIHR, or the UK Department of Health. We thank all patients and 
their families for participating in this study, all staff involved at the 
Articles
174 www.thelancet.com/oncology   Vol 21   January 2020
17 participating hospitals, and the staff involved in the trial at the Cancer 
Biomarkers Group at ICR, at the Prostate Cancer Targeted Therapy 
Group at the Royal Marsden Hospital (London, UK), and at ICR­CTSU. 
Finally, we thank the past and present colleagues of the TOPARP trial 
management group, the TOPARP­B independent data monitoring 
committee, and the ICR­CTSU steering committee for trials in 
metastatic castration­resistant prostate cancer.
References
1 Attard G, Parker C, Eeles RA, et al. Prostate cancer. Lancet 2016; 
387: 70–82.
2 Armenia J, Wankowicz SAM, Liu D, et al. The long tail of oncogenic 
drivers in prostate cancer. Nat Genet 2018; 50: 645–51.
3 Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical 
genomics of advanced prostate cancer. Cell 2015; 162: 454.
4 Quigley DA, Dang HX, Zhao SG, et al. Genomic hallmarks and 
structural variation in metastatic prostate cancer. Cell 2018; 
174: 758–69.e9.
5 Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair 
defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 
434: 917–21.
6 Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2­
deficient tumours with inhibitors of poly(ADP­ribose) polymerase. 
Nature 2005; 434: 913–17.
7 Kaufman B, Shapira­Frommer R, Schmutzler RK, et al. Olaparib 
monotherapy in patients with advanced cancer and a germline 
BRCA1/2 mutation. J Clin Oncol 2015; 33: 244–50.
8 Pujade­Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as 
maintenance therapy in patients with platinum­sensitive, relapsed 
ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT­Ov21): 
a double­blind, randomised, placebo­controlled, phase 3 trial. 
Lancet Oncol 2017; 18: 1274–84.
9 Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance 
therapy in patients with platinum­sensitive relapsed serous ovarian 
cancer: a preplanned retrospective analysis of outcomes by BRCA 
status in a randomised phase 2 trial. Lancet Oncol 2014; 15: 852–61.
10 Murai J, Huang SY, Renaud A, et al. Stereospecific PARP trapping 
by BMN 673 and comparison with olaparib and rucaparib. 
Mol Cancer Ther 2014; 13: 433–43.
11 Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 
by clinical PARP inhibitors. Cancer Res 2012; 72: 5588–99.
12 Mateo J, Carreira S, Sandhu S, et al. DNA­repair defects and 
olaparib in metastatic prostate cancer. N Engl J Med 2015; 
373: 1697–708.
13 Scher HI, Halabi S, Tannock I, et al. Design and end points of 
clinical trials for patients with progressive prostate cancer and 
castrate levels of testosterone: recommendations of the Prostate 
Cancer Clinical Trials Working Group. J Clin Oncol 2008; 
26: 1148–59.
14 Eisenhauer EA, Therasse P, Bogaerts J, et al. New response 
evaluation criteria in solid tumours: revised RECIST guideline 
(version 1.1). Eur J Cancer 2009; 45: 228–47.
15 Mateo J, Moreno V, Gupta A, et al. An adaptive study to determine 
the optimal dose of the tablet formulation of the PARP inhibitor 
olaparib. Target Oncol 2016; 11: 401–15.
16 Seed G, Yuan W, Mateo J, et al. Gene copy number estimation from 
targeted next­generation sequencing of prostate cancer biopsies: 
analytic validation and clinical qualification. Clin Cancer Res 2017; 
23: 6070–77.
17 Scher HI, Heller G, Molina A, et al. Circulating tumor cell 
biomarker panel as an individual­level surrogate for survival in 
metastatic castration­resistant prostate cancer. J Clin Oncol 2015; 
33: 1348–55.
18 Yap C, Pettitt A, Billingham L. Screened selection design for 
randomised phase II oncology trials: an example in chronic 
lymphocytic leukaemia. BMC Med Res Methodol 2013; 13: 87.
19 Meeks HD, Song H, Michailidou K, et al. BRCA2 polymorphic stop 
codon K3326X and the risk of breast, prostate, and ovarian cancers. 
J Natl Cancer Inst 2016; 108: djv315.
20 Goodall J, Mateo J, Yuan W, et al. Circulating cell­free DNA to guide 
prostate cancer treatment with PARP inhibition. Cancer Discov 2017; 
7: 1006–17.
21 Sandhu SK, Schelman WR, Wilding G, et al. The poly(ADP­ribose) 
polymerase inhibitor niraparib (MK4827) in BRCA mutation 
carriers and patients with sporadic cancer: a phase 1 dose­escalation 
trial. Lancet Oncol 2013; 14: 882–92.
22 de Bono J, Ramanathan RK, Mina L, et al. Phase I, dose­escalation, 
two­part trial of the PARP inhibitor talazoparib in patients with 
advanced germline BRCA1/2 mutations and selected sporadic 
cancers. Cancer Discov 2017; 7: 620–29.
23 Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP­ribose) 
polymerase in tumors from BRCA mutation carriers. N Engl J Med 
2009; 361: 123–34.
24 Wu YM, Cieslik M, Lonigro RJ, et al. Inactivation of CDK12 
delineates a distinct immunogenic class of advanced prostate 
cancer. Cell 2018; 173: 1770–82.e14.
25 Tutt A, Robson M, Garber JE, et al. Oral poly(ADP­ribose) 
polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 
mutations and advanced breast cancer: a proof­of­concept trial. 
Lancet 2010; 376: 235–44.
26 Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP­ribose) 
polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 
mutations and recurrent ovarian cancer: a proof­of­concept trial. 
Lancet 2010; 376: 245–51.
27 Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA­repair gene 
mutations in men with metastatic prostate cancer. N Engl J Med 
2016; 375: 443–53.
28 Alexandrov LB, Nik­Zainal S, Wedge DC, et al. Signatures of 
mutational processes in human cancer. Nature 2013; 500: 415–21.
29 Cruz C, Castroviejo­Bermejo M, Gutiérrez­Enríquez S, et al. 
RAD51 foci as a functional biomarker of homologous 
recombination repair and PARP inhibitor resistance in germline 
BRCA­mutated breast cancer. Ann Oncol 2018; 29: 1203–10.
30 Abida W, Bryce AH, Vogelzang NJ, et al. Preliminary results from 
TRITON2: a phase 2 study of rucaparib in patients with metastatic 
castration­resistant prostate cancer (mCRPC) associated with 
homologous recombination repair (HRR) gene alterations. 
Ann Oncol 2018; 29 (suppl 8): vii271–302.
31 Clarke N, Wiechno P, Alekseev B, et al. Olaparib combined with 
abiraterone in patients with metastatic castration­resistant prostate 
cancer: a randomised, double­blind, placebo­controlled, phase 2 
trial. Lancet Oncol 2018; 19: 975–86.
